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The incidence of pancreatic cancer increases with age, suggesting that chronological aging is a significant risk factor for
this disease. Fibroblasts are the major nonmalignant cell type
in the stroma of human pancreatic ductal adenocarcinoma
(PDAC). In this study, we investigated whether the chronological aging of normal human fibroblasts (NHFs), a previously
underappreciated area in pancreatic cancer research, influences
the progression and therapeutic outcomes of PDAC. Results
from experiments with murine xenografts and 2D and 3D cocultures of NHFs and PDAC cells revealed that older NHFs stimulate proliferation of and confer resistance to radiation therapy
of PDAC. MS-based metabolite analysis indicated that older
NHFs have significantly increased arachidonic acid 12-lipoxygenase (ALOX12) expression and elevated levels of its mitogenic
metabolite, 12-(S)-hydroxy-5,8,10,14-eicosatetraenoic acid (12(S)-HETE) compared with their younger counterparts. In cocultures with older rather than with younger NHFs, PDAC cells
exhibited increases in mitogen-activated protein kinase signaling and cellular metabolism, as well as a lower oxidation state
that correlated with their enhanced proliferation and resistance
to radiation therapy. Expression of ALOX12 was found to be
significantly lower in PDAC cell lines and tumor biopsies, suggesting that PDAC cells rely on a stromal supply of mitogens for
their proliferative needs. Pharmacological (hydroxytyrosol) and
molecular (siRNA) interventions of ALOX12 in older NHFs suppressed their ability to stimulate proliferation of PDAC cells.
We conclude that chronological aging of NHFs contributes to
PDAC progression and that ALOX12 and 12-(S)-HETE may be
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potential stromal targets for interventions that seek to halt progression and improve therapy outcomes.

The incidence of pancreatic cancer increases with age;
median age at diagnosis is 71 years old and the median age at
death is 73 years old, suggesting that chronological aging is a
significant risk factor for pancreatic cancer. Pancreatic ductal
adenocarcinoma (PDAC)2 ranks fourth among cancer-related
deaths in the United States: it has a very high incidence of recurrence and a dismal 5-year survival rate of less than 8% (1, 2)
(RRID: SCR_006902). Recent evidence suggests that the tumor
microenvironment significantly influences progression and
therapy of cancer (4 –10). PDAC tissue is stroma-rich, dense,
and fibrous (11, 12). The stroma of PDAC includes fibroblasts,
myofibroblasts, stellate cells, immune cells, and endothelial
cells (8). Fibroblasts are the major noncancerous cell type contributing to the cellularity of the stroma that include synthesis
and remodeling of the extracellular matrix as well as the production of secretory and nonsecretory factors that influence
cancer cell proliferation and progression to end stage disease.
Because age is a significant risk factor for PDAC, it is important
to know whether the age of the stroma influences progression
of PDAC and the mechanisms involved in this process.
Chronologically aged normal human fibroblasts (NHF) (quiescent fibroblasts aged in vitro) are known to stimulate proliferation of human breast cancer cells (13). C-C motif chemokine
ligand 5, which is overexpressed in chronologically aged NHFs,
has been shown to activate the extracellular signal-regulated
kinase (ERK)1/2-cyclin D1 pathway in breast cancer cells
resulting in the stimulation of their proliferation (13). Although
quiescent cells are not actively proliferating, they are metabolically active. Significant changes in metabolism have been
observed during chronological aging of NHFs (14). Metabolism
2
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of quiescent cultures of NHFs from younger (newborn to 1 year
old) donors were found to be more glycolytic compared with
NHFs from older (29 –70 years old) donors that exhibited significant increases in mitochondrial respiration. These previously published results led us to the novel hypothesis that an
age-related change in metabolism of the stroma contributes to
the progression of epithelial cancer.
An increase in mitochondrial respiration and decrease in glycolysis in older NHFs suggest that changes in lipid metabolism
during aging can influence stroma-directed progression of
PDAC. Lipid-signaling pathways are known to regulate proliferation and therapy of cancer cells (15–19). Eicosanoids are a
family of lipid mediators derived from the metabolism of
arachidonic acid (AA). AA is converted to eicosanoids by
cyclooxygenase and arachidonic acid lipoxygenase (ALOX)
enzymes. Based on their regiospecificity, human ALOXs are
grouped into three major groups: ALOX5, ALOX12, and
ALOX15. The enzymatic products of ALOXs are hydroperoxyeicosatetraenoic acids, which are converted to hydroxyeicosatetraenoic acids (HETEs) (20, 21). 12-(S)-HETE is a mitogenic metabolite of ALOX12. The signaling and mitogenic
properties of 12-(S)-HETE can be mediated by its binding to the
membrane-bound G protein– coupled receptors; GPR31 is a
high-affinity receptor for 12-(S)-HETE (22). Eicosanoids, which
include prostaglandins and leukotrienes, are well-known for
their inflammation and immune properties (23). These lipid
mediators are also known to have mitogenic properties (23, 24).
Results from this study show that the chronological aging of
the stroma regulates progression and radiation therapy resistance of PDAC. ALOX12 and 12-(S)-HETE are potential targets
of the aging stroma that can be considered to halt progression
and improve therapy of PDAC.

Results
NHFs from older healthy donors stimulate proliferation of
PDAC cells
To determine whether chronological aging of NHFs regulates progression of PDAC, we used a novel murine xenograft
approach where co-cultures of CellTracker Green-labeled
NHFs and luciferase expressing MIA PaCa-2 cells (10:1)
embedded in injectable tissue-like 3D gel matrix were injected
into the flank of 30-day-old athymic female nude mice
(Foxn1nu). Bioluminescence imaging system (Xenogen IVIS200) was used to measure proliferation. Results clearly show the
presence of CellTracker Green-labeled NHFs and luciferase
expressing MIA PaCa-2 cells in the xenograft (Fig. 1A). The
presence of NHFs in tumors was also evident from the confocal
microscopy analysis of excised tumor tissues (Fig. 1B) and flow
cytometry analysis of cell suspensions prepared from resected
tumors (Fig. 1C). Measurements of tumor volume showed 2⫻
tumor volume in xenografts carrying co-cultures of MIA
PaCa-2 cells and NHFs from a 61-year-old healthy donor compared with tumor volume in co-cultures of MIA PaCa-2 cells
and NHFs from a 3-day-old healthy donor. Increases in tumor
volume correlated with a shorter median survival of a 34-dayold compared with a median survival of 44 days of mice carrying
xenograft of MIA PaCa-2 cells and NHFs from a 3-day-old

Figure 1. Older NHFs stimulate proliferation of MIA PaCa-2 human PDAC
cells in vivo. A, 3D gel matrix-embedded co-cultures of CellTracker Greenlabeled NHFs and luciferase expressing MIA PaCa-2-Luc cells were injected
into the flank of mice, and imaged when palpable tumors were detected. n ⫽
2. B, H&E and fluorescent microscopy detection of NHFs (yellow arrows) and
MIA PaCa-2 cells (white arrows). C, flow cytometry analysis of cell suspensions
prepared from excised tumors: CellTracker Green-positive (NHFs) and negative (MIA PaCa-2-Luc) cells. D, tumor volume of co-cultures of NHFs and MIA
PaCa-2 cells; inset shows representative resected tumors. Asterisks represent
significance; mean ⫾ S.D.; n ⫽ 10, p ⬍ 0.05. E, Kaplan-Meyer plot of survival;
n ⫽ 10, p ⬍ 0.05.

donor (Fig. 1, D and E). An age-related stimulation of proliferation of MIA PaCa-2 cells in co-cultures of older compared
with young NHFs was also observed in an orthotopic xenograft
approach (Fig. S1). Overall, these results support our novel
hypothesis that chronological aging of the stroma regulates
progression of PDAC.
Results from these in vivo experiments were also recapitulated in 3D and 2D co-cultures in vitro. A mixture of luciferase
expressing MIA PaCa-2-Luc cells and quiescent cultures of
NHFs (10:1) were embedded into the Cell Mate 3D matrix and
co-cultured for different days. Photon counts showed approximately a 4-fold increase of MIA PaCa-2-Luc cells co-cultured
with quiescent cultures of NHFs from a 61-year-old healthy
donor (Fig. 2, A and B). The doubling time of MIA PaCa-2-Luc
cells co-cultured with NHFs from a 61-year-old donor was ⬃20
h compared with a doubling time of 60 h for MIA PaCa-2-Luc
cells co-cultured with NHFs from a 3-day-old donor (Fig. 2B).
Similar to the co-existence of MIA PaCa-2-Luc cells and NHFs
in tumor xenograft in vivo (Fig. 1, A–C), results from H&E
staining and fluorescence microscopy also showed the presence
of NHFs (black arrow) and MIA PaCa-2 cells (white arrow) in
the 3D co-cultures (Fig. 2B, inset), suggesting that the 3D coculture method can partially mimic the tumor microenvironment in vitro.
To determine whether the age of the stroma can also influence therapy of PDAC, 3D co-cultures of quiescent NHFs and
PDAC-Luc cells were irradiated with a shortened clinical protocol, 2 Gy ⫻ 5 days. Results showed that the rate of proliferation of MIA PaCa-2-Luc cells is consistently higher in irradiJ. Biol. Chem. (2020) 295(20) 6946 –6957
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Figure 2. Chronological aging of NHFs influences progression and therapy of human PDAC cells in 3D co-cultures. A, pseudo-color scale of photons s⫺1 emitted from individual 3D spheres of co-cultures of NHFs and MIA
PaCa-2-luc cells. B, photon counts of MIA PaCa-2-luc cells in co-cultures; inset
shows H&E staining of sliced spheres: fibroblasts (black arrows), cancer cells
(white arrows). Photon counts of (C) MIA PaCa-2-Luc and (D) PANC-1-Luc cells
in 3D co-cultures of NHFs post-radiation (2 Gy ⫻ 5 days). Asterisks represent
significance; n ⫽ 3, p ⬍ 0.05.

ated co-cultures of NHFs from a 61-year-old donor at 4 –12
days post-irradiation compared with co-cultures with NHFs
from a 3-day-old healthy donor (Fig. 2C). Comparable results
were also obtained from co-cultures using a separate PDAC cell
line, PANC-1-Luc (Fig. 2D). These results support the hypothesis that chronological aging of the stroma significantly affects
proliferation and radiation therapy of PDAC cells.
The age difference between the two NHFs (61 years old versus 3 days old) and our earlier observation of chronological
aging of NHFs stimulating proliferation of breast cancer cells
(13, 25–27) suggest that the chronological aging of the stroma
can significantly influence progression of PDAC. To further
investigate this hypothesis, quiescent cultures of NHFs from a
3-day-old donor were aged in vitro for 7 (early) and 60 (late)
days. CellTracker Green-labeled MIA PaCa-2 cells were then
added on top of the unlabeled quiescent lawns of NHFs. 2D
co-cultures of MIA PaCa-2 cells and NHFs were continued in
vitro for an additional 2– 6 days. Microscopy imaging and flow
cytometry methods (13) were used to measure proliferation of
MIA PaCa-2 cells in co-cultures of NHFs. Microscopy evaluation of the density of MIA PaCa-2 cells showed a significant
increase in proliferation of MIA PaCa-2 cells co-cultured with
late-NHFs (3-fold increase at 6 days of co-culture) (Fig. 3A).
The doubling time for MIA PaCa-2 cells co-cultured with quiescent cultures of late-NHFs was calculated to be 23 h compared with a doubling time of 33 h for MIA PaCa-2 cells co-cultured with early-NHFs (Fig. 3B). These results were further
confirmed by flow cytometry analysis of the percentage of MIA
PaCa-2 cells in co-cultures of early- and late-NHFs; there was
more than 60% increase in the number of MIA PaCa-2 cells
co-cultured with late-NHFs compared with early-NHFs (Fig.
3C). These results clearly show that quiescent cultures of NHFs
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that are chronologically aged in vitro also promote proliferation
of PDAC cells. To rigorously test this novel observation of
chronological aging affecting progression of PDAC, additional
2D co-culture experiments were performed using NHFs from
donors of different ages. Results showed a significant increase
in the percentage of MIA PaCa-2 cells from 7% in co-cultures of
quiescent cultures of NHFs from a 3-day-old donor to 18 and
30% in co-cultures with NHFs from 12- and 61-year-old healthy
donors, respectively (Fig. 3, D and E). Comparable results were
also observed in co-cultures of NHFs and PANC-1 and BxPC-3
PDAC cell lines (Fig. 3E). Additionally, a small but statistically
significant increase in proliferation of nonmalignant H6c7 pancreatic ductal epithelial cells was also observed in co-cultures of
NHFs from a 61-year-old donor (Fig. 3E). These results showed
that the chronological aging of NHFs promotes proliferation of
both malignant and nonmalignant pancreatic ductal epithelial
cells, but the growth stimulatory effects are significantly higher
in malignant compared with nonmalignant cells.
Results from the 3D co-culture experiments demonstrating
radiation resistance of PDAC cells in co-cultures of old compared with young NHFs (Fig. 2D) were also recapitulated in
experiments using 2D co-cultures. CellTracker Green-labeled
MIA PaCa-2 cells were layered upon confluent cultures of
NHFs from 3-day-old and 12- and 61-year-old healthy donors.
Co-cultures at 5 days post-plating were irradiated with 0, 2, and
4 Gy ionizing radiation and continued in culture. The percentage of CellTracker Green-labeled MIA PaCa-2 cells in control
and irradiated co-cultures was analyzed by flow cytometry.
Results showed a significant increase in the percentage of MIA
PaCa-2 cells in un-irradiated control co-cultures of 12- and
61-year-old compared with 3-day-old NHFs; approximately, 15
and 30% MIA PaCa-2 cells in co-cultures of 12- and 61-year-old
NHFs compared with 5% MIA PaCa-2 cells in co-cultures of
3-day-old NHFs (Fig. 4A). Co-cultures irradiated with 4 Gy
radiation showed a significant decrease in the percentage of
MIA PaCa-2 cells in all co-cultures compared with their respective un-irradiated controls (Fig. 4A). However, the decrease in
the percentage of MIA PaCa-2 cells in irradiated co-cultures of
61-year-old NHFs was significantly less than co-cultures with
12-year-old and 3-day-old NHFs (Fig. 4A), further suggesting
that aging NHFs confer radiation resistance of MIA PaCa-2
cells. Indeed, flow cytometry analysis of radiation-induced toxicity of MIA PaCa-2 cells in co-cultures of NHFs showed maximal cell death in co-cultures of 3-day compared with 12- and
61-year-old NHFs (Fig. 4B). Overall, these results showed that
quiescent cultures of NHFs from donors of older compared
with younger healthy individuals stimulate proliferation and
induce radiation therapy resistance of PDAC cells (Figs. 1– 4).
ALOX12 and 12-(S)-HETE mediate fibroblasts’ chronological
aging-induced stimulation of proliferation of PDAC cells
We previously reported significant increases in mitochondrial respiration rates and decreases in glycolytic flux in NHFs
from 29 –70 –year-old healthy donors (14), demonstrating that
changes in cellular metabolism occur during chronological
aging of NHFs. To determine whether specific metabolic processes are altered during chronological aging, metabolomics
profiling was performed (University of Iowa Metabolomics
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Figure 3. Older NHFs stimulate proliferation of PDAC cells in 2D co-cultures. A, microscopy pictures of 5-day co-cultures of NHFs and CellTracker Greenlabeled MIA PaCa-2 cells. B, growth of CellTracker Green-labeled MIA PaCa-2 cells in co-cultures of NHFs. C, flow cytometry analysis of MIA PaCa-2 cells in
co-cultures of NHFs. D, representative flow cytometry histograms showing distributions of NHFs and MIA PaCa-2 cells in co-cultures. E, percentage of PDAC cells
in co-cultures of NHFs from donors of different ages. Asterisks represent significance; n ⫽ 3, p ⬍ 0.05.

Figure 4. Resistance of MIA PaCa-2 cells to radiation treatments in 2D
co-cultures of old compared with young NHFs. CellTracker Green-labeled
MIA PaCa-2 cells were layered over confluent cultures of NHFs from 3-dayand 12- and 61-year-old healthy donors. At the end of 5 days of co-cultures,
cells were irradiated with 0, 2, and 4 Gy of ionizing radiation. Flow cytometry
was used to identify and quantitate CellTracker Green-positive (MIA PaCa-2)
and negative (NHFs) cells. Proliferation of MIA PaCa-2 cells was assessed from
the decreases in CellTracker Green fluorescence per cell. A, percent of MIA
PaCa-2 cells in control and irradiated co-cultures of NHFs; B, percent of MIA
PaCa-2 cell death in control and irradiated co-cultures; n ⫽ 3, p ⬍ 0.05.

Core Facility). A semi-targeted high-resolution GC-MS protocol was used to quantitatively measure metabolites of the TCA
cycle, glycolytic intermediates, amino acids, sugars, and fatty
acids. Results showed significant increases in fatty acids levels
of NHFs from older healthy donors, mostly in the 18 –22 carbon
fatty acids (Fig. 5A). Among this group of fatty acids, levels of
AA (C20:4) showed an increase of ⬃2-fold. AA is converted to
eicosanoids by cyclooxygenase and ALOX enzymes. Initially, a

RT-qPCR assay was performed to determine whether an agerelated increase in AA metabolism could be due to an increase
in the expression of prostaglandin-endoperoxide synthase
(PTGS-1 and -2) and arachidonic acid lipoxygenase (ALOX5,
-12, and -15) enzymes. Results showed no significant difference
in the expression of PTGS-1 and -2, and ALOX5 and ALOX15
between the 61-year- and 3-day-old NHFs. However, a significant difference in the expression of ALOX12 was observed in
the 61-year-old NHFs: a ⬃6-fold increase in mRNA levels (Fig.
5B) and 2-fold increase in protein levels (Fig. 5B, inset). This
intriguing observation of an age-related increase in ALOX12
expression was further evident from a corresponding increase
in its secreted metabolite, 12-(S)-HETE. Levels of 12-(S)-HETE
were significantly lower (⬍10 fg cell⫺1) in NHFs from a 3-dayand 5-month-old healthy donor compared with 10 –35 fg cell⫺1
in NHFs from the 58 –70 –year-old group (Fig. 5C). To further
verify that the increases in 12-(S)-HETE levels are true representation of the chronological aging process, NHFs from a
3-day healthy donor were aged in quiescence for 7 (early) and 60
(late) days. Consistent with the results of 12-(S)-HETE levels in
NHFs from donors of different ages (Fig. 5C), early-NHFs
showed significantly lower levels of 12-(S)-HETE (⬍10 fg
cell⫺1) compared with more than 20 fg cell⫺1 in late-NHFs (Fig.
5D). Overall, these results showed significant increases in the
expression of ALOX12 and its metabolite, 12-(S)-HETE during
the chronological aging of NHFs.
Considering the mitogenic property of 12-(S)-HETE (28, 29),
we hypothesize that 12-(S)-HETE secreted from the aging
stroma stimulates proliferation of PDAC cells via a paracrine
signaling pathway. To test this novel hypothesis, we first measured mRNA levels of ALOX12 in established PDAC cell lines
(MIA PaCa-2 and PANC-1), recently generated patient-derived
PDAC cell lines (339 and 403), and a transformed but nonmalignant (H6c7) human pancreatic epithelial cell line. Expression
of ALOX12 in all four PDAC cell lines was significantly lower
compared with its expression in the nonmalignant cell line,
H6c7 (Fig. 5, E and F). Next, we examined whether the receptor
J. Biol. Chem. (2020) 295(20) 6946 –6957
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Figure 5. An age-related increase in ALOX12 expression and 12-(S)-HETE is associated with old NHFs-induced stimulation of PDAC cells. A, mass
spectrometry analysis of lipid metabolites in conditioned media of 3-day-old and 61-year-old NHFs. Fold-change was calculated relative to metabolites in
3-day-old NHFs. B, RT-qPCR analysis of arachidonic acid-metabolizing enzymes; inset shows immunoblot analysis of ALOX12. An ELISA-based assay was used
to quantitatively measure 12-(S)-HETE levels in conditioned media collected from: C, quiescent cultures of NHFs from donors of different ages and D, 3-day-old
NHFs that were aged in culture. RT-qPCR analysis: ALOX12 expression in: E, PDAC cell lines obtained from ATCC and F, newly generated PDAC cell lines from
surgically resected and de-identified human PDAC tissues. G, RT-qPCR analysis of GPR31 mRNA expression. H, proliferation of MIA PaCa-2 cells in the presence
of exogenously added 12-(S)-HETE. Asterisks represent significance; n ⫽ 3, p ⬍ 0.05.

for 12-(S)-HETE, GPR31, is differentially expressed in normal
compared with PDAC cells. Expression of GPR31 was found to
be significantly lower in NHFs and H6c7 cells compared with a
6 –14 –fold increase in the PDAC cell lines (Fig. 5G). These
results suggest that whereas 12-(S)-HETE secreted from NHFs
may not affect their own proliferation because of significantly
lower expression of GPR31 and quiescent growth state, they
can have a paracrine effect on neighboring PDAC cells that
have significantly higher expression of GPR31. This premise is
supported from results presented in Fig. 5H. A dose-dependent
increase in the number of MIA PaCa-2 cells was observed when
different concentrations (1–10 fg cell⫺1) of 12-(S)-HETE were
added to the medium and cells were cultured for 24 – 48 h (Fig.
5H). Overall, these results suggest that 12-(S)-HETE secreted
from the aging stroma initiates a paracrine mitogenic effect that
results in enhanced proliferation of PDAC cells.
Increases in MAPK signaling pathways and metabolism
combined with a lower oxidation status of PDAC cells in
co-cultures of old NHFs
We have previously shown that quiescent cultures of 3-day
NHFs aged in vitro induced ERK1/2-cyclin D1 proliferative
pathway in human breast cancer cells resulting in their
enhanced proliferation (13). To determine whether older
NHFs-induced proliferation of PDAC cells (Figs. 1– 4) is associated with the induction of MAPK pathways, MIA PaCa-2 cells
were first separated from co-cultures of NHFs by flow cytometry-based cell sorting. RayBiotech MAPK pathway phosphorylation arrays were used to measure the phosphorylation status
of pro-proliferative signaling proteins. Although phosphorylation (active form) of most of the proliferative-signaling proteins
increased in MIA PaCa-2 cells co-cultured with 61-year-old

6950 J. Biol. Chem. (2020) 295(20) 6946 –6957

Figure 6. Metabolic and proliferative signaling pathways are enhanced
in PDAC cells co-cultured with older NHFs. RayBiotech MAPK Pathway
Phosphorylation Arrays were used to analyze the phosphorylation status of
signaling proteins of MIA PaCa-2 cells sorted from co-cultures of NHFs. Visualization and quantification of results were performed using a Typhoon 7000
phosphorimager (GE Healthcare) and NIH ImageJ software. Left panels,
images of the original blots and heat maps; right panel, quantitative results.
Percent increase in phosphoproteins of 61-year-old NHFs was calculated relative to 3-day-old NHFs.

compared with 3-day-young NHFs, increases in the ERK1/2,
and mTOR signaling pathways were more pronounced (Fig. 6).
These results suggest that increases in the ERK1/2 and mTOR
signaling pathways can mediate enhanced proliferation of
PDAC cells in co-cultures of old compared with young NHFs.
Increases in glucose and mitochondrial metabolism during
progression from G0-G1 to S-G2-M phases suggest that cellular
metabolism is intimately linked to cellular proliferation (30). To
determine whether chronological aging of NHFs alters the
metabolism of PDAC cells that results in their enhanced proliferation, flow cytometry-based cell sorting was used first to separate MIA PaCa-2 cells from 2D co-cultures of quiescent NHFs
and then metabolites of MIA PaCa-2 cells were analyzed using
a Thermo Q Exactive GC-MS Orbitrap instrument (UIOWA

Stromal aging and pancreatic cancer progression

Figure 7. Increases in metabolism combined with a lower oxidation status of PDAC cells co-cultured with old compared with young NHFs. A, flow
cytometry sorted MIA PaCa-2 cells from co-cultures of CellTracker Green-labeled NHFs were used for analysis of metabolites (UIOWA HCCC Metabolomics Core). Results were normalized to cell mass and fold-change calculated
relative to metabolites of MIA PaCa-2 cells co-cultured with 3-day-old NHFs. B
and C, flow cytometry analysis of DHE-oxidation in co-cultures of CellTracker
Green-labeled NHFs and MIA PaCa-2 cells. Asterisk represents significance
compared with 3-day-old NHFs; n ⫽ 3, p ⬍ 0.05.

HCCC Metabolomics Core). Results showed significant increases in the metabolites of the glycolytic (glucose, fructose
6-phosphate, lactate, and pyruvate) and pentose phosphate
pathway (PPP: ribose 5-phosphate and sedoheptulose 7-phosphate) in MIA PaCa-2 cells co-cultured with NHFs from a
61-year-old compared with a 3-day-old healthy donor (Fig. 7A).
These results suggest that increases in cellular metabolism of
PDAC cells can mediate their enhanced proliferation in co-cultures of old compared with young NHFs.
To determine whether older NHFs-induced increases in glycolysis and PPP of MIA PaCa-2 cells also impact their redox
status, co-cultures were incubated with dihydroethidium
(DHE). DHE oxidation was analyzed by flow cytometry (30).
Consistent with results presented in Fig. 3, the percentage of
the MIA PaCa-2 cells was higher in co-cultures of quiescent
NHFs from the 61-year-old compared with 3-day-old healthy
donor (Fig. 7B). It is interesting to note that the DHE oxidation
was significantly lower in MIA PaCa-2 cells co-cultured with
NHFs from the 61-year-old compared with 3-day-old healthy
donor (Fig. 7C). These results suggest that older NHFs facilitate
a reducing environment of MIA PaCa-2 cells by rewiring their
metabolism to glycolysis and PPP. Overall, these results (Figs. 6
and 7) suggest that older NHFs promote proliferation of PDAC
cells by enhancing the MAPK signaling pathways and cellular
metabolism that favor a reducing environment supporting proliferation of PDAC cells.
Pharmacological and molecular interventions of ALOX12 and
12-(S)-HETE in older NHFs suppress their abilities to stimulate
proliferation of PDAC cells
There is growing interest in the use of polyphenols to minimize age-related health issues (31–33). Hydroxytyrosol, a

major polyphenol of olives, has been shown to inhibit activity of
ALOX12 (34 –36). To determine whether hydroxytyrosol treatment affects 12-(S)-HETE levels in NHFs, quiescent cultures of
NHFs from a 61-year-old donor were cultured in medium containing 100 M hydroxytyrosol. An ELISA-based assay was used
to measure 12-(S)-HETE in conditioned medium. Results
showed more than 50% decrease in 12-(S)-HETE levels in
hydroxytyrosol-treated NHFs compared with untreated controls (Fig. 8A). Consistent with earlier results (Figs. 1– 4), quiescent cultures from a 61-year-old healthy donor stimulated
proliferation of MIA PaCa-2 cells as evident from the significant increase in the percentage of MIA PaCa-2 cells in co-cultures of NHFs (Fig. 8B, upper panels). However, such an
increase in proliferation of MIA PaCa-2 cells is significantly
suppressed in co-cultures of hydroxytyrosol-treated quiescent
cultures of NHFs (Fig. 8B, lower panels). Comparable results
were also obtained when experiments were repeated using
3-day-old NHFs that were chronologically aged in vitro. Plating
efficiency of MIA PaCa-2 cells cultured in conditioned medium
collected from control treatment increased to 40% in conditioned medium collected from late-NHFs compared with 20%
in medium collected from early-NHFs (Fig. 8C). However, plating efficiency of MIA PaCa-2 cells cultured in conditioned
medium collected from hydroxytyrosol-treated early- and lateNHFs is significantly suppressed (Fig. 8C). These results suggest a role of 12-(S)-HETE regulating proliferation of MIA
PaCa-2 cells in co-cultures of NHFs.
The causality of ALOX12 regulating old NHF-induced stimulation of proliferation of PDAC cells was also investigated
using a siRNA molecular approach. Treatment with siALOX12
decreased its expression by ⬃50% in NHFs from a 61-year-old
donor (Fig. 8D, upper panel). Flow cytometry analysis of 2D
co-cultures that were performed using CellTracker Green-labeled NHFs and MIA PaCa-2 cells showed a significant
decrease in the percentage of MIA PaCa-2 cells (⬃35%) co-cultured with siALOX12-treated NHFs compared with 50% in cocultures with control and scramble-siRNA treated NHFs (Fig.
8D, lower panel). Overall, results from the pharmacological and
molecular approaches clearly showed a mechanistic role of
ALOX12 and its metabolite 12-(S)-HETE regulating old NHFs
induced stimulation of proliferation of PDAC cells.
Clinical correlation of ALOX12 and 12-(S)-HETE with PDAC
progression and therapy
The clinical significance of our basic science research was
determined by measuring ALOX12 and 12-(S)-HETE in PDAC
patients’ samples. Initially, the Oncomine database was used to
analyze microarray transcriptome profiling data that were collected by Buchholz et al. (37) from pancreatic intraepithelial
neoplastic lesions, pancreas intraepithelial neoplasia, pancreas
ductal adenocarcinoma, and normal pancreas duct. Bioinformatics evaluation of these data set revealed a significant downregulation of the expression of ALOX12 in pancreas carcinoma
compared with pancreas cancer precursor and normal pancreas duct (Fig. 9A). Using de-identified surgical samples of
PDAC and plasma samples (provided by Dr. J. Cullen; samples
were collected from a Phase I trial, NCT number 01852890 for
PDAC therapy) (38), we examined protein expression of
J. Biol. Chem. (2020) 295(20) 6946 –6957
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Figure 8. Hydroxytyrosol and siALOX12 treatments suppress older NHFs induced stimulation of PDAC proliferation. A, 12-(S)-HETE levels in conditioned media from 10-day quiescent cultures of control and 100 M hydroxytyrosol-treated NHFs. B, flow cytometry analysis of the percentage of MIA PaCa-2
cells in co-cultures of CellTracker Green-labeled control and hydroxytyrosol-treated NHFs. C, plating efficiency of MIA PaCa-2 cells cultured in conditioned
media from control and hydroxytyrosol-treated NHFs. Asterisks represent statistical significance; n ⫽ 3, p ⬍ 0.05. D, upper panel: immunoblot analysis of ALOX12
protein levels in control, scrambled siRNA, and siALOX12 treated 61-year-old NHFs. Lower panel: flow cytometry analysis of the percentage of MIA PaCa-2 cells
in co-cultures of NHFs.

ALOX12 in biopsies and 12-(S)-HETE levels in plasma samples.
Results showed that the protein levels of ALOX12 were significantly lower in PDAC cells compared with nearby nonmalignant cells (Fig. 9B), which is also consistent with the Oncomine
data (Fig. 9A). A higher level of 12-(S)-HETE was observed in all
patients’ plasma samples post-therapy compared with pretherapy (Fig. 9C). Within the post-therapy samples, a correlation was observed between 12-(S)-HETE levels and incidence of
recurrence and metastasis: higher levels of 12-(S)-HETE correlating with higher incidence of recurrence and metastasis in
PDAC patients (Fig. 9, D and E). These results attest to the
clinical significance of our basic science research. In summary,
results from this study showed the significance of the chronological aging of normal human fibroblasts in pancreatic cancer
and identified ALOX12 and 12-(S)-HETE as novel molecular
regulators of stromal aging-induced progression and therapy
outcomes of PDAC (Fig. 9F).

Discussion
Like all cancers, the incidence of PDAC increases exponentially with age (3). Although a majority of PDAC research
focuses on understanding the cellular and molecular control of
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the epithelial cancer cells, we investigated whether the chronological aging of normal cells regulates progression and therapy
outcomes of PDAC, and the mechanisms involved in this process. Our results showed fibroblasts from older healthy donors
stimulate proliferation and confer resistance to radiation therapy of human PDAC cells. Results from pharmacological and
molecular approaches identified ALOX12 and its metabolite
12-(S)-HETE contributing to older fibroblasts’ induced stimulation of proliferation and radiation resistance of PDAC cells.
Replicative and chronological lifespan are two of the most
widely studied modes of cellular aging (39 –41). Chronological
lifespan represents the duration of quiescence during which
normal cells retain their capacity to re-enter the proliferative
cycle (25, 26). We previously reported that the chronological
aging of fibroblasts is independent of mitotic division and
telomerase activity (25). Our results also showed quiescent cultures of NHFs from a 3-day-old healthy donor that were chronologically aged in culture to stimulate proliferation of human
breast cancer cells (13). The present study was designed to
investigate whether naturally aged NHFs influence progression
and therapy of PDAC cells. Results from in vivo murine xenograft of co-cultures of NHFs and human MIA PaCa-2 cells
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Figure 9. ALOX12 and 12-(S)-HETE are potential stromal-aging biomarkers for PDAC progression and therapy response. A, Oncomine data analysis of
ALOX12 expression in pancreas cancer (37). B, immunohistochemistry analysis of ALOX12 in paraffin-embedded and de-identified resected PDAC tissues: black
arrows, PDAC cells; yellow arrows, nonmalignant stromal cells. C, 12-(S)-HETE levels in de-identified plasma samples from 14 PDAC patients. Results were
evaluated for incidence of (D) recurrence and (E) metastasis. Asterisks represent significance, p ⬍ 0.05, measured by paired t test. F, an illustration showing
increases in ALOX12 expression and 12-(S)-HETE levels during chronological aging of NHFs promoting PDAC progression by enhancing MAPK signaling
pathways and metabolism. It is hypothesized that increases in metabolism combined with a reducing status confer resistance of PDAC cells to therapy in an
aging-stromal environment.

showed a higher tumor volume in co-cultures of older NHFs
and MIA PaCa-2 cells, which was also associated with a lower
median survival (Fig. 1, D and E). Comparable results were also
obtained from 3D and 2D co-cultures of MIA PaCa-2 cells and
quiescent cultures of NHFs from donors of different ages (Figs.
2, A and B, and 3). Similar results were also obtained from 2D
co-culture experiments that were performed using PANC-1
and BxPC-3 PDAC cells (Fig. 3E). A small but statistically significant increase in the proliferation of H6c7 (transformed but
nonmalignant) human pancreatic epithelial cells was also
observed (Fig. 3E). NHFs’ age-induced proliferation of PDAC
cells appear to be independent of the k-ras genotype status of
PDAC cells. Older NHFs stimulated proliferation of both WT
(BxPC-3) and mutant (MIA PaCa-2 and PANC-1) k-ras cells
(Fig. 2A). Additional results showed that the older NHFs confer
radiation resistance of MIA PaCa-2 and PANC-1 cells (Figs. 2,
C and D, and 4). Overall, our earlier results of chronologically

aged in vitro cultures of NHFs stimulating proliferation of
breast cancer cells (13) and results (Figs. 1– 4) from this study
clearly show that the chronological aging of NHFs is a critical
factor in progression and therapy outcomes of PDAC.
In 1966 Stoker et al. (42) first reported quiescent cultures of
rodent fibroblasts inhibiting proliferation of polyoma-transformed rodent fibroblasts. Flaberg et al. (43) used a highthroughput live-cell imaging method to study the effects of 107
human fibroblasts on proliferation of human prostate cancer
cells in vitro. Although all primary cultures of fibroblasts inhibited growth of the prostate cancer cells, pediatric fibroblasts
showed a higher inhibitory effect compared with adult fibroblasts. Although the authors did not address the age effect of
these fibroblasts, their results did invoke the hypothesis that the
age of the stroma (fibroblasts) is a significant factor in epithelial
cancer progression. Indeed, laser capture microdissection and
gene expression analysis of human breast cancer tissues did
J. Biol. Chem. (2020) 295(20) 6946 –6957
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show a distinct stromal-aging footprint in older compared with
younger patients (44). Consistent with these literature reports,
our results also showed an age-effect of NHFs stimulating proliferation of PDAC cells (Figs. 1– 4). Based on single-cell transcriptomic analysis, recent studies report the presence of at
least three different types of fibroblasts in the PDAC stroma:
fibroblasts exhibiting myofibroblastic features (␣SMAhigh) that
surround the malignant PDAC and fibroblasts exhibiting
inflammatory (cytokine and chemokine positive) and antigenpresenting properties that reside distally from the PDAC cells
(45–47). Based on our observation of higher ALOX12 expression and higher levels of its metabolite 12-(S)-HETE (inflammatory signature) in older NHFs (Fig. 5), we speculate that the
distally localized fibroblasts with the inflammatory phenotype
represent the aging stroma and they contribute to the stromal
age-related progression of PDAC.
We previously reported a shift in cellular metabolism from
glycolysis in young to mitochondrial respiration in older NHFs
(14). Decreases in extracellular acidification rates and increases
in oxygen consumption rates during chronological lifespan of
NHFs (14) suggest that metabolic pathways other than glycolysis are involved with the age-related increases in respiration of
NHFs. Mitochondrial respiration also receives substrates from
lipid metabolism, suggesting that the age-related increases in
respiration of NHFs could be due to a change in their lipid
metabolism. Indeed, results from MS analysis of metabolites
showed significant increases in free fatty acid levels of older
compared with young NHFs (Fig. 5A). An age-related increase
in AA metabolism of NHFs was also evident from the corresponding increases in the expression of ALOX12 and its mitogenic metabolite, 12-(S)-HETE (Fig. 5, B–D). It is interesting to
note that the expression of ALOX12 was significantly lower in
established (Fig. 5E) and newly generated (Fig. 5F) patient-derived PDAC cell lines, whereas the expression of GPR31 (receptor for 12-(S)-HETE) was significantly higher in PDAC cells
compared with NHFs and H6c7 nonmalignant pancreatic epithelial cells (Fig. 5, E–G). These results support the hypothesis
that a paracrine signaling from older NHFs provides a mitogenic environment for PDAC cells. Although 12-(S)-HETE
secreted from older NHFs may not stimulate their own proliferation due to a lower level of expression of GPR31, it is anticipated to provide mitogenic stimuli to PDAC cells due to their
higher level of expression of GPR31. Indeed, exogenously added
12-(S)-HETE dose-dependently enhanced proliferation of MIA
PaCa-2 cells (Fig. 5H).
Consistent with our earlier results of chronologically aged
3-day NHFs enhancing the ERK1/2 pathway that resulted in
significant increases in proliferation of breast cancer cells (13),
results from the MAPK arrays also showed significant increases
in the ERK1/2 and mTOR pathways in MIA PaCa-2 cells that
were associated with their enhanced proliferation in co-cultures of old compared with young NHFs (Fig. 6). As anticipated,
increases in the ERK1/2 and mTOR pathways were also associated with increases in cellular metabolism (glycolysis and PPP)
of MIA PaCa-2 cells in co-cultures of old compared with young
NHFs (Fig. 7A). Whereas the nonoxidative pathway of the PPP
is involved in nucleotide biosynthesis (ribose 5-phosphate), the
oxidative pathway of the PPP promotes a reducing environ-
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ment (NADPH, GSH). Indeed, old NHFs-induced increases in
the PPP of MIA PaCa-2 cells were associated with a lower oxidation status compared with the oxidation status of MIA
PaCa-2 cells co-cultured with young NHFs (Fig. 7, B and C). A
lower oxidation status (reducing environment) is anticipated to
favor proliferation and therapy resistance of MIA PaCa-2 cells
in co-cultures of old compared with young NHFs. This premise
is consistent with results presented in Figs. 1–7.
Results from pharmacological and molecular approaches
clearly showed a role of ALOX12 and 12-(S)-HETE contributing to old NHF-induced proliferation of PDAC cells (Fig. 8).
Because expression of ALOXs is down-regulated in human
bladder, breast, lung, colon, and prostate cancer cells (3, 48, 49),
our results also suggest that ALOXs and their metabolites HEPTEs and HETEs provide a stromal aging-derived mitogenic axis
that promotes cancer progression and confer resistance to therapy. The clinical significance of our basic science research is
evident from our observation of a significant decrease in
ALOX12 expression in PDAC cells compared with their neighboring nonmalignant cells as well as plasma levels of 12-(S)HETE correlating with therapy outcomes, recurrence, and
metastasis (Fig. 9, A–E).
In summary, our results showed that the chronological aging
of NHFs is a critical regulator of progression and therapy outcomes of PDAC. Intervention of the aging stroma by targeting
ALOX12 expression (Fig. 9F) can be a novel approach to prevent progression and improve therapy of PDAC.

Experimental procedures
Additional details of the experimental procedures are included under the “Supporting Materials”.
Cell culture and reagents
All cell cultures (Table S1) were performed using Dulbecco’s
modified Eagle’s medium (Gibco) supplemented with 10% fetal
bovine serum and antibiotics in humidified incubators with
ambient oxygen concentration. Measurements in NHFs were
performed using individual and primary cultures from donors
of different ages; samples were not pooled. Microscopy and
flow cytometry assays were used to visualize and quantitate the
percentage of NHFs and PDAC cells in co-cultures. Luciferase
expressing PDAC cells and Cell Mate 3D Gel matrix (BRTI Life
Sciences) were used for the 3D co-culture experiments. Photon
counts (Xenogen IVIS 200 system) were used to measure proliferation of luciferase expressing PDAC cells in 3D co-cultures.
Hydroxytyrosol was purchased from the Cayman Chemical. A
shortened clinical radiation therapy protocol (2 Gy ⫻ 5 days;
dose rate 0.6 Gy min⫺1) was used to irradiate co-cultures.
Murine tumor xenograft
All animal experiments were reviewed and approved by the
Animal Care and Use Committee of The University of Iowa;
approval number 1311211-001. Cell Mate 3D Gel matrix-embedded co-cultures of CellTracker Green-labeled NHFs and
luciferase expressing MIA PaCa-2 cells (10:1) were injected into
the flank of 5-week-old female athymic mice, and imaged when
palpable tumors were detected. Microscopy and flow cytometry methods were used to identify NHFs and MIA PaCa-2 cells
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in the excised xenograft. In a separate set of experiments, tumor
volume of xenograft carrying co-cultures of NHFs and MIA
PaCa-2 cells was measured using a digital caliper.
Analysis of metabolites
A ThermoQ Exactive Mass Spectrometer (The UIOWA
Metabolomics Core Facility) was used to analyze metabolites in
cells and conditioned media. Xcailbur Tracefinder 4.1 software
was used for data analysis.

Statistical methods
SPSS software was used for all statistical analysis. For experiments with three or more continuous variables, statistical analysis was performed using the one- or two-way analysis of variance with Tukey’s honestly significant difference. Homogeneity
of variance is assumed with 95% confidence interval level.
Results from at least n ⱖ 3 with p ⬍ 0.05 are considered significant. Group survival was summarized with Kaplan-Meier plots
and compared with log-rank and Gehan-Breslow-Wilcoxon
tests.

RT-qPCR assay
Total cellular RNA was extracted using TRIzol reagent
(Invitrogen) and quantified using a NanoDrop-1000 Spectrophotometer (Thermo Fisher Scientific). One microgram of
total RNA was reverse-transcribed using High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems). cDNAs were
used for Real-Time PCR amplification using the Power SYBR
Green Master Mix (Applied Biosystems) and StepOne PlusTM
System (Applied Biosystems) following our published method
(30).
siRNA knockdown
Quiescent cultures of NHFs were transfected with scrambled
(SR30004) and siALOX12 (SR300166; OriGene) using Lipofectamine 2000 (Invitrogen) following the manufacturers protocol. Immunoblotting assay was used to measure the efficiency
of siRNA knockdown of ALOX12 expression at 48 –96 h
post-transfection.
Immunoblotting assay
Cell pellets were pulse-sonicated (Vibra-Cell Cup Horn; Sonics and Materials Inc.) and equal amounts of protein lysates
were separated on SDS-PAGE followed by semi-dry electroblotting to nitrocellulose membrane (Bio-Rad Labs). Membranes were incubated with antibodies to human ALOX12
(Milipore-Sigma) and ␤-actin (Abcam). PierceTM ECL 2 Western blotting Substrate (Thermo Scientific) and Typhoon FLA
7000 (GE Healthcare) were used to visualize immune-reactive
polypeptides.
Immunohistochemistry assay
De-identified PDAC tissues and plasma samples were
obtained from Dr. Cullen’s recently completed phase I trial
(NCT number 01852890) designed to examine the safety of
pharmacological ascorbate with gemcitabine for the treatment
of pancreatic cancer. Paraffin-embedded and de-identified surgical tissue sections were dewaxed and processed for analysis of
ALOX12 expression using primary ALOX12 antibody (Millipore-Sigma), horseradish peroxidase-linked secondary antibody, and 3,3⬘-diaminobenzidine as the chromogen. Slides
were counterstained with Harris hematoxylin and images were
recorded using microscopy.
ELISA
Enzo life Sciences ELISA kit (ADI-900-050) was used to
quantify 12-(S)-HETE levels in plasma samples of 14 PDAC
patients.

Data availability
All the data described are contained within the manuscript
and associated supporting information.
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